The importance of QTPP in biotech

Safeguarding safety and efficacy from day one

Failing to clearly define quality targets early in biotech development can have serious repercussions. Minor deviations in critical attributes can affect patient safety, delay regulatory approval, and increase costs through batch failures or rework. The Quality Target Product Profile (QTPP) plays a vital role as the guiding framework that sets quality expectations for your drug product from day one.

What is the QTPP?

At its core, the QTPP is a forward-looking summary of the key quality attributes your product must meet. This includes dosage form, strength, route of administration, release profile, stability, and performance requirements. Establishing these criteria early focuses your development on clear, patient-centric goals, avoiding costly specification changes later when adjustments become difficult or impossible.

Why defining QTPP matters

Protecting patient safety and therapeutic effectiveness

Biotech medicines, especially biologics and advanced therapies, are inherently complex. Small changes in formulation or manufacturing can dramatically alter how a drug behaves in the body. The QTPP helps you identify Critical Quality Attributes (CQAs) - measurable properties that must be tightly controlled to maintain safety and efficacy. These include impurity levels, biological activity, stability profiles, and release kinetics.

Providing a roadmap for development

From formulation design to process scale-up, the QTPP aligns activities around defined quality targets. It helps teams anticipate challenges, focus R&D, and build robust manufacturing and control strategies that reduce late-stage surprises and compliance risks.

Facilitating regulatory approval

Regulators like the EMA and FDA expect a science- and risk-based approach known as Quality by Design (QbD). QbD shows how quality is built into the product, not just tested at the end. A well-defined QTPP connected to CQAs demonstrates this rigor and can speed up regulatory review by showing clear control over variability.

Enabling continuous improvement

The QTPP is not static. As new data emerges, for example from scale-up studies or clinical trials, it should be reviewed and refined to adapt to new insights, maintain compliance, and enhance product quality.

Connecting QTPP to Quality by Design (QbD)

The QTPP forms the basis of the QbD framework. It defines the CQAs that guide the selection of Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs). This chain supports a robust control strategy that manages variability and ensures that every batch meets quality requirements.

For instance, if your QTPP specifies 24-month stability for a biologic injectable, CQAs like potency, aggregation, and residual host cell proteins become the focus of tight controls during development. Using Design of Experiments (DoE) and Process Analytical Technology (PAT) allows you to understand how variations impact these attributes, reducing the risk of batch failures.

The role of analytical method development

Robust analytical methods are the backbone of verifying your CQAs. Advanced biotech products often require sensitive, highly specific methods, for example using orthogonal assays to confirm biological activity or detect impurities at low levels.

Key best practices include:

• Method validation: Ensure methods are validated for accuracy, precision, specificity, and robustness, as required by ICH Q2(R2).

• Method lifecycle management: Continuously monitor method performance to detect drifts or variability that could impact results.

• Platform approaches: For biologics, platform analytical methods (e.g., for monoclonal antibodies) can accelerate timelines while ensuring comparability across lots.

• Advanced technologies: Use modern tools like mass spectrometry, multi-attribute methods (MAM), or next-generation sequencing (NGS) for detailed characterization when appropriate.

A poorly developed analytical package can undermine even a well-crafted QTPP, so invest early to ensure your methods can reliably confirm your product meets its defined profile.

Regulatory expectations in practice

The FDA has emphasized in its guidance that failure to align a product’s QTPP with clearly defined CQAs, and lacking sensitive analytical methods, can result in regulatory delays or requests for additional data. For example, the FDA’s Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs), issued in January 2020, requires sponsors to demonstrate robust impurity profiling and use validated, sensitive assays capable of detecting low‑level impurities, variants, and contaminants that could impact patient safety or product consistency.

In practice, failure to meet these expectations often leads to additional FDA requests for data or new manufacturing runs to confirm product control, adding time, cost, and reputation risk. Conversely, a robust QTPP linked to well‑validated analytical methods and clearly mapped CQAs demonstrates that quality is built into the product from the start, reducing the likelihood of regulatory setbacks.

Practical advice for biotech teams

• Start early: Define your QTPP at project initiation to anchor development around patient-focused quality goals.

• Identify CQAs thoughtfully: Use risk assessment tools like ICH Q9 to focus on attributes directly affecting safety and efficacy.

• Build robust analytical methods: Validate assays early and design for lifecycle monitoring to maintain data integrity.

• Work cross-functionally: Encourage close collaboration among formulation scientists, process engineers, analytical teams, and regulatory experts.

• Partner with experts: Engage CDMOs and consultants experienced in QTPP, QbD, and complex method development.

• Keep it dynamic: Revisit and refine your QTPP and CQAs as new data becomes available to support continuous improvement.

Ignoring a clearly defined QTPP and its supporting analytical framework can lead to unexpected failures, prolonged development cycles, and costly delays. The upfront investment pays off in smoother regulatory reviews, faster time to market, and, ultimately, safer, more effective products for patients.

3Biotech can help you get it right from the start. With expertise spanning analytical development, process optimisation, and regulatory strategy, we guide your biotech project with science-first precision and risk-based control.

Ready to reduce risks and accelerate success? Book a call with our team today.

Book a call